NCT05060341 is a clinical trial in Radiation-induced Xerostomia, sponsored by MeiraGTx, LLC.

Who is sponsoring NCT05060341?

NCT05060341 is sponsored by MeiraGTx, LLC.

What condition does NCT05060341 study?

NCT05060341 studies Radiation-induced Xerostomia.

Is NCT05060341 still recruiting?

NCT05060341 is currently active, enrolled. Last updated 19 May 2025.

Last reviewed 2025-05-19 · How we verify

NCT05060341

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Long-Term Follow-Up Study of Participants Enrolled in the MGT016 Phase 1, Open-Label, Dose-Escalation Study of AAV2hAQP1 for Radiation-Induced Parotid Gland Hypofunction and Xerostomia

Active, enrolled Last updated 19 May 2025

What this trial tests

trial in Radiation-induced Xerostomia in 22 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

12 November 2020

Primary endpoint
1 March 2027

1 March 2027

Quick facts

Lead sponsor	MeiraGTx, LLC
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	22
Start date	12 November 2020
Primary completion	1 March 2027
Estimated completion	1 March 2027
Sites	4 locations across United States, Canada

Conditions studied

Radiation-induced Xerostomia — all drugs for Radiation-induced Xerostomia →

Sponsor

MeiraGTx, LLC — full company profile →

Who can join

Adults 18 to 81, any sex, with Radiation-induced Xerostomia.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Incidence of AEs, treatment-emergent adverse events (TEAEs), and SAEs
Time frame: 4 years
Safety

Sponsor's own description

This study is a long-term follow-up study for patients who have been administered AAV2hAQP1 in the Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity in Subjects with Radiation Induced Parotid Gland Hypofunction and Xerostomia

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Radiation-induced Xerostomia

Currently open trials in the same condition.

NCT07035626 — A Randomized Controlled Trial of Spermidine for the Prevention of Radiation-Induced Xerostomia in Head and Neck Squamous · Phase 1, PHASE2 · recruiting

Other MeiraGTx, LLC trials

Trials by the same sponsor.

NCT05603312 — A Double-blind Study to Evaluate the Safety of Glutamic Acid Decarboxylase Gene Transfer in Parkinson's Participants · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05060341 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MeiraGTx, LLC
Last refreshed: 19 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060341.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing